Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Open-label, Single-arm Trial of Ganaxolone in CDD Patients 6 Months to Less Than 2 Years Old

30 de octubre de 2026 actualizado por: Immedica Pharma AB

An Open-label, Single-arm, 52-week, Multicenter Phase 3 Trial to Assess Pharmacokinetics, Safety, Tolerability, and Activity of Adjunctive Ganaxolone for the Treatment of Seizures Associated With Genetically Confirmed Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) in Pediatric Patients From 6 Months to Less Than 2 Years of Age

The goal of this clinical trial is to learn how patients with CDKL-5 deficiency disorder (CDD) aged 6 months to 2 years of age respond to treatment with ganaxolone. The main questions the trial aims to answer are:

  • The amount of the medicine that was in participants' bodies and the safety of the medicine.
  • Does the medicine ganaxolone lower the number of seizures when used in addition to the participant's usual anti-seizure treatment.

Participants will:

Take ganaxolone 3 times daily for up to 52 weeks. Visit the clinic every 3 to 5 weeks for the initial 17 weeks of the trial and thereafter every 11 to 12 weeks.

The participant's caregiver will:

Keep a daily diary of the participants seizures and use of anti-seizure medications, including the trial drug ganaxolone.

Descripción general del estudio

Estado

Aún no reclutando

Intervención / Tratamiento

Descripción detallada

This is an open-label, single-arm, 52-week, multicenter trial of adjunctive ganaxolone treatment in participants 6 months to less than 2 years of age with genetically confirmed CDD. The trial consists of an up to 2-week Screening Period, 4-week prospective Baseline Period, followed by 2 parts: Part A; a 17-week ganaxolone treatment phase (including 4 to 5 weeks of ganaxolone titration followed by 12 to 13 weeks of dose maintenance) and Part B; a 35-week ganaxolone maintenance phase, and a 2-week taper period at the end of the trial. Tapering will not apply for participants continuing ganaxolone treatment after the trial.

The Screening Period will follow the Screening Visit to ensure caregivers can classify seizures and comply with completion instructions of an electronic seizure and medication diary. This will be followed by a 4-week prospective Baseline Period to assess seizure frequency for trial eligibility.

Up to 15 participants will be enrolled to ensure at least 12 participants are evaluable for the primary PK endpoints at the end of Part A of the trial, including at least 3 participants experiencing uncontrolled seizures despite treatment with at least 2 anti-seizure medications.

Participants will be monitored at Baseline and at specified visits to assess the exposure, safety and tolerability and activity of ganaxolone. PK samples will be collected at specified timepoints up until completion of Part A.

Clinical laboratory testing will be performed at local laboratories at participating sites.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

12

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Clinical Project Manager
  • Número de teléfono: +46 8 533 39 500
  • Correo electrónico: clinical@immedica.com

Copia de seguridad de contactos de estudio

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

6 meses a 2 años (Niño)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Key Inclusion Criteria:

  1. A diagnosis of CDD, including molecular confirmation of a pathogenic or likely pathogenic CDKL5 variant.

  2. Male or female participants aged 6 months to less than 2 years at the Baseline Visit.

  3. Failure to control seizures despite appropriate use of 1 or more anti-seizure medications at therapeutic doses. At least 3 participants will be included who failed to control seizures despite appropriate use of at least 2 anti-seizure medications.

  4. Participants will have refractory seizures with a history of at least 8 countable seizures of primary seizure types during the 28 days prospective Baseline Period prior to the Baseline Visit. Primary seizure types are seizures with or without impairment of consciousness with a clear motor component, including generalized tonic-clonic, focal to bilateral tonic-clonic, atonic/drop, bilateral clonic, bilateral tonic (sustained motor activity ≥ 3 seconds). Clusters of uncountable seizures will be counted as a single seizure.

    1. Primary seizures exclude epileptic spasms. Patients with epileptic spasms are eligible for enrolment but epileptic spasms will not be counted as qualifying countable seizures for eligibility. Epileptic spasms should not constitute the dominant seizure type during the Baseline Period.
    2. Primary seizures exclude myoclonic, absence, generalized non-motor seizures, and focal motor or non-motor seizures with or without impairment of awareness.
  5. Participants should be receiving a stable regimen of anti-seizure medications at Screening through to the end of the 4-week prospective Baseline Period and have no foreseeable change for the duration of Part A.

    1. Concurrent use of adrenocorticotropic hormone, prednisone, other glucocorticoids, or vigabatrin are permitted.
    2. Vagus nerve stimulator (VNS) settings, ketogenic diet, or a modified Atkins diet should be unchanged for 1 month prior to the Screening Visit, throughout the Screening Period and the 4-week prospective Baseline Period and without foreseeable change for the duration of Part A at the time of the Baseline Visit.
  6. Parent/caregiver is able and willing to maintain an accurate and complete daily seizure diary for the duration of the trial.

Key Exclusion Criteria:

  1. Have an active CNS infection, demyelinating disease, degenerative neurological disease, or CNS disease deemed progressive as evaluated by brain imaging (magnetic resonance imaging).
  2. Have any disease or condition (medical or surgical; other than CDKL5 deficiency) that might compromise the hematologic, cardiovascular, pulmonary, renal, gastrointestinal, or hepatic systems; or other conditions that might interfere with the absorption, distribution, metabolism, or excretion of the investigational product or would place the participant at increased risk.
  3. History of or present AST (aspartate aminotransferase/serum glutamic-oxaloacetic transaminase) or ALT (alanine aminotransferase/serum glutamic-pyruvic transaminase) >3 times the upper limit of normal (ULN) at Baseline and confirmed by a repeat testing.
  4. History of or present total bilirubin levels greater than the ULN at trial Baseline and confirmed by a repeat testing. In cases of a documented, stable medical condition (i.e., Gilbert's Syndrome) resulting in levels of total bilirubin greater than the ULN, the Medical Monitor will determine if an exception can be made.
  5. Participants with significant renal insufficiency, with an estimated glomerular filtration rate (eGFR) <30 mL/min (calculated using the Cockcroft-Gault formula or Pediatric eGFR calculator or Bedside Schwartz).
  6. Regular use of St. John's Wort or strong CYP3A4 inducers, e.g., phenytoin, carbamazepine or phenobarbital (N.B. phenytoin and phenobarbital are permitted as rescue medication on as-need basis but are not permitted as continuous maintenance medication).
  7. Have been exposed to any other investigational drug within 30 days or less than its 5 half-lives prior to the Screening Visit.
  8. Previous treatment with ganaxolone.
  9. Participation in any other trial involving administration of an investigational medication or device.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Ganaxolone

Ganaxolone sodium benzoate-free oral suspension 50 mg/ml

Ganaxolone

Otros nombres:
  • Droga activa
  • Ztalmy

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Ganaxolone exposure in participants receiving ganaxolone doses up to 63 mg/kg/day
Periodo de tiempo: Baseline through 17 weeks

Pharmacokinetic (PK) exposure parameter derived from population PK modelling and simulation: steady-state maximum concentration (Cmax,ss)

Baseline through 17 weeks
Ganaxolone exposure in participants receiving ganaxolone doses up to 63 mg/kg/day
Periodo de tiempo: Baseline through 17 weeks

PK exposure parameter derived from population PK modelling and simulation: trough concentration (Ctrough)

Baseline through 17 weeks
Ganaxolone exposure in participants receiving ganaxolone doses up to 63 mg/kg/day
Periodo de tiempo: Baseline through 17 weeks

PK exposure parameter derived from population PK modelling and simulation: systemic exposure (Caverage,ss derived as AUC over a dosing interval / tau)

Baseline through 17 weeks
Safety and tolerability of ganaxolone as adjunctive therapy for the treatment of seizures in participants receiving ganaxolone doses up to 63 mg/kg/day
Periodo de tiempo: Baseline through to 52 weeks

Frequency, type, and severity of adverse events (AEs)

Baseline through to 52 weeks

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Ganaxolone PK parameters at steady-state in participants receiving ganaxolone doses up to 63 mg/kg/day.
Periodo de tiempo: Baseline through to 17 weeks

Non-compartmental-like steady-state PK parameters derived from population PK modelling and simulation: steady-state time to maximum concentration (tmax,ss)

Baseline through to 17 weeks
Ganaxolone PK parameters at steady-state in participants receiving ganaxolone doses up to 63 mg/kg/day.
Periodo de tiempo: Baseline through to 17 weeks

Non-compartmental-like steady-state PK parameters derived from population PK modelling and simulation: exposure accumulation ratios

Baseline through to 17 weeks
Ganaxolone PK parameters at steady-state in participants receiving ganaxolone doses up to 63 mg/kg/day.
Periodo de tiempo: Baseline through to 17 weeks

Non-compartmental-like steady-state PK parameters derived from population PK modelling and simulation: swing [(Cmax-Cmin)/Cmin])

Baseline through to 17 weeks
Activity of ganaxolone as adjunctive therapy for the treatment of primary seizures at the end of the 17-week treatment period (Part A)
Periodo de tiempo: Baseline through to 17 weeks

Percent change from baseline in 28-day primary seizure frequency during the treatment period relative to the 4-week prospective Baseline Phase

Baseline through to 17 weeks
Activity of ganaxolone as adjunctive therapy for the treatment of primary seizures at the end of the 17-week treatment period (Part A)
Periodo de tiempo: Baseline through to 17 weeks

Percentage of participants experiencing ≥50% reduction in the 28-day primary seizure frequency compared to the 4-week baseline

Baseline through to 17 weeks
Activity of ganaxolone as adjunctive therapy for the treatment of primary seizures at the end of the 17-week treatment period (Part A)
Periodo de tiempo: Baseline through to 17 weeks

Percent change in seizures by primary seizure type

Baseline through to 17 weeks
Activity of ganaxolone as adjunctive therapy for the treatment of primary seizures at the end of the 17-week treatment period (Part A)
Periodo de tiempo: Baseline through to 17 weeks

Percent change in primary seizure-free days

Baseline through to 17 weeks
Activity of ganaxolone as adjunctive therapy for the treatment of primary seizures at the end of the 17-week treatment period (Part A)
Periodo de tiempo: Baseline through to 17 weeks

Clinical Global Impression of Improvement (CGI-I); 7-point Likert scale, higher scores mean a worse outcome

Baseline through to 17 weeks
Activity of ganaxolone as adjunctive therapy for the treatment of primary seizures at the end of the 17-week treatment period (Part A)
Periodo de tiempo: Baseline through to 17 weeks

Caregiver Global Impression of Change in Seizure Intensity/Duration (CGI-CSID); 7-point Likert scale, higher scores mean a worse outcome

Baseline through to 17 weeks
Activity of ganaxolone as adjunctive therapy for the treatment of primary seizures at the end of the 52-week treatment period (Part B)
Periodo de tiempo: Baseline through to 52 weeks

Percent change from baseline in 28-day primary seizure frequency during the treatment period relative to the 4-week prospective Baseline Phase

Baseline through to 52 weeks
Activity of ganaxolone as adjunctive therapy for the treatment of primary seizures at the end of the 52-week treatment period (Part B)
Periodo de tiempo: Baseline through to 52 weeks

Percentage of participants experiencing ≥50% reduction in the 28-day primary seizure frequency compared to the 4-week baseline

Baseline through to 52 weeks
Activity of ganaxolone as adjunctive therapy for the treatment of primary seizures at the end of the 52-week treatment period (Part B)
Periodo de tiempo: Baseline through to 52 weeks

Percent change in seizures by primary seizure type

Baseline through to 52 weeks
Activity of ganaxolone as adjunctive therapy for the treatment of primary seizures at the end of the 52-week treatment period (Part B)
Periodo de tiempo: Baseline through to 52 weeks

Percent change in primary seizure-free days

Baseline through to 52 weeks
Activity of ganaxolone as adjunctive therapy for the treatment of primary seizures at the end of the 52-week treatment period (Part B)
Periodo de tiempo: Baseline through to 52 weeks

Clinical Global Impression of Improvement (CGI-I); 7-point Likert scale, higher scores mean a worse outcome

Baseline through to 52 weeks
Activity of ganaxolone as adjunctive therapy for the treatment of primary seizures at the end of the 52-week treatment period (Part B)
Periodo de tiempo: Baseline through to 52 weeks

Caregiver Global Impression of Change in Seizure Intensity/Duration (CGI-CSID); 7-point Likert scale, higher scores mean a worse outcome

Baseline through to 52 weeks

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de marzo de 2027

Finalización primaria (Estimado)

1 de diciembre de 2029

Finalización del estudio (Estimado)

1 de diciembre de 2029

Fechas de registro del estudio

Enviado por primera vez

27 de enero de 2022

Primero enviado que cumplió con los criterios de control de calidad

18 de febrero de 2022

Publicado por primera vez (Actual)

21 de febrero de 2022

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

4 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

30 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 1042-CDD-3002
  • 2026-528611-26-00 (Ctis)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir